S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Kodiak Sciences Stock Forecast, Price & News

+2.31 (+2.11 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume190,187 shs
Average Volume292,980 shs
Market Capitalization$5.76 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KOD News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

Kodiak Sciences logo

About Kodiak Sciences

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$19.21 per share


Net Income
$-133.10 million




Market Cap
$5.76 billion
Next Earnings Date
11/8/2021 (Estimated)


Overall MarketRank

2.16 out of 5 stars

Medical Sector

417th out of 1,361 stocks

Biological Products, Except Diagnostic Industry

62nd out of 196 stocks

Analyst Opinion: 2.2Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Kodiak Sciences (NASDAQ:KOD) Frequently Asked Questions

Is Kodiak Sciences a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Kodiak Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KOD, but not buy additional shares or sell existing shares.
View analyst ratings for Kodiak Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Kodiak Sciences?

Wall Street analysts have given Kodiak Sciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kodiak Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kodiak Sciences' next earnings date?

Kodiak Sciences is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Kodiak Sciences

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) issued its quarterly earnings results on Monday, August, 9th. The company reported ($1.08) EPS for the quarter, missing the Zacks' consensus estimate of ($0.98) by $0.10.
View Kodiak Sciences' earnings history

How has Kodiak Sciences' stock price been impacted by Coronavirus?

Kodiak Sciences' stock was trading at $53.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KOD shares have increased by 107.9% and is now trading at $111.97.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KOD?

11 Wall Street analysts have issued 12 month target prices for Kodiak Sciences' stock. Their forecasts range from $86.00 to $170.00. On average, they expect Kodiak Sciences' stock price to reach $131.09 in the next twelve months. This suggests a possible upside of 17.1% from the stock's current price.
View analysts' price targets for Kodiak Sciences
or view top-rated stocks among Wall Street analysts.

Who are Kodiak Sciences' key executives?

Kodiak Sciences' management team includes the following people:
  • Victor Perlroth, Chairman & Chief Executive Officer
  • John Borgeson, Chief Financial Officer & Senior Vice President
  • Jason S. Ehrlich, Chief Medical & Development Officer (LinkedIn Profile)
  • Sinette Heys, Vice President-Clinical Operations
  • Pablo Velazquez-Martin, VP-Clinical Research & Translational Medicine

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and Axon Enterprise (AAXN).

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the NASDAQ under the ticker symbol "KOD."

How do I buy shares of Kodiak Sciences?

Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $111.97.

How much money does Kodiak Sciences make?

Kodiak Sciences has a market capitalization of $5.76 billion. The company earns $-133.10 million in net income (profit) each year or ($2.91) on an earnings per share basis.

How many employees does Kodiak Sciences have?

Kodiak Sciences employs 72 workers across the globe.

What is Kodiak Sciences' official website?

The official website for Kodiak Sciences is kodiak.com.

Where are Kodiak Sciences' headquarters?

Kodiak Sciences is headquartered at 2631 HANOVER STREET, PALO ALTO CA, 94304.

How can I contact Kodiak Sciences?

Kodiak Sciences' mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The company can be reached via phone at (650) 281-0850 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.